Equillium, Inc. (EQ)
Market Cap | 23.97M |
Revenue (ttm) | 37.89M |
Net Income (ttm) | -12.13M |
Shares Out | 35.25M |
EPS (ttm) | -0.35 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 94,223 |
Open | 0.680 |
Previous Close | 0.678 |
Day's Range | 0.650 - 0.701 |
52-Week Range | 0.450 - 3.250 |
Beta | 1.81 |
Analysts | Strong Buy |
Price Target | 3.90 (+473.53%) |
Earnings Date | Aug 7, 2024 |
About EQ
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lu... [Read more]
Financial Performance
In 2023, Equillium's revenue was $36.08 million, an increase of 128.97% compared to the previous year's $15.76 million. Losses were -$13.34 million, -78.64% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for EQ stock is "Strong Buy." The 12-month stock price forecast is $3.9, which is an increase of 473.53% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/j/r/conf8-2506811.jpg)
Equillium to Participate in Upcoming Investor Conferences
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/d/2/press6-2475387.jpg)
Equillium to be included in the Russell Microcap® Index
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/a/l/press2-2463447.jpg)
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/m/o/press6-2461214.jpg)
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat s...
![](https://cdn.snapi.dev/images/v1/k/b/conf11-2451389.jpg)
Equillium to Present at the Jefferies Global Healthcare Conference
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/q/n/press10-2429234.jpg)
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/m/f/press18-2422480.jpg)
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat s...
![](https://cdn.snapi.dev/images/v1/x/y/press8-2414523.jpg)
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/s/b/press17-2350750.jpg)
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/7/o/press11-2340649.jpg)
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...
![](https://cdn.snapi.dev/images/v1/d/e/conf4-2337274.jpg)
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/m/f/press4-2204876.jpg)
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/y/v/press12-2154686.jpg)
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #lupus--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammat...
![](https://cdn.snapi.dev/images/v1/h/y/press18-2147974.jpg)
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...
![](https://cdn.snapi.dev/images/v1/d/u/press8-2141375.jpg)
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammato...
![](https://cdn.snapi.dev/images/v1/p/a/press19-2110915.jpg)
Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #lupus--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammat...
![](https://cdn.snapi.dev/images/v1/n/x/press18-2104366.jpg)
Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory diso...
![](https://cdn.snapi.dev/images/v1/2/v/press6-2087514.jpg)
Equillium to Host Analyst & Investor Day
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/e/p/conf9-2085632.jpg)
Equillium to Present at the JonesTrading 2023 Healthcare Summit
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/x/r/conf15-2070809.jpg)
Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/k/7/conf18-2042865.jpg)
Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...
![](https://cdn.snapi.dev/images/v1/n/k/press17-2015663.jpg)
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...
![](https://cdn.snapi.dev/images/v1/d/h/press4-2002453.jpg)
Equillium Announces $7.5 Million Share Repurchase Program
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...
![](https://cdn.snapi.dev/images/v1/q/z/conf9-1916325.jpg)
Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/z/t/press15-1886231.jpg)
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...